Detalhe da pesquisa
1.
Thrombotic and bleeding complications in patients with AL amyloidosis.
Br J Haematol
; 204(5): 1816-1824, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38321638
2.
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study.
Haematologica
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38356458
3.
Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma.
Am J Hematol
; 2024 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38860642
4.
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy.
Br J Haematol
; 203(3): 411-415, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37580907
5.
Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Hematol Oncol
; 41(4): 725-732, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36974438
6.
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies.
Eur J Haematol
; 111(2): 271-278, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37218632
7.
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.
Int J Mol Sci
; 24(14)2023 Jul 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37511588
8.
Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.
Br J Haematol
; 196(2): 356-359, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34528249
9.
Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist.
Am J Hematol
; 97(1): 119-128, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34687462
10.
SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies.
Am J Hematol
; 97(10): 1300-1308, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35871310
11.
Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications.
Am J Hematol
; 97(9): 1142-1149, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35731917
12.
Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance.
Br J Haematol
; 193(1): 113-118, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32829529
13.
Biomarkers in AL Amyloidosis.
Int J Mol Sci
; 22(20)2021 Oct 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34681575
14.
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.
Blood
; 131(14): 1568-1575, 2018 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29386197
15.
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period.
Ann Hematol
; 99(6): 1257-1264, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32382768
16.
Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma.
Ann Hematol
; 99(6): 1251-1255, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32307566
17.
Solid Organ Transplantation in Amyloidosis.
Acta Haematol
; 143(4): 352-364, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32535598
18.
Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome.
Ann Hematol
; 98(6): 1427-1434, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30834954
19.
Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates.
Am J Hematol
; 94(4): 400-407, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30592079
20.
Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study.
Am J Hematol
; 99(3): 502-504, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38270219